Translation of structure‐activity relationships from cyclic mixed efficacy opioid peptides to linear analogues
dc.contributor.author | Anand, Jessica P. | en_US |
dc.contributor.author | Porter‐barrus, Vanessa R. | en_US |
dc.contributor.author | Waldschmidt, Helen V. | en_US |
dc.contributor.author | Yeomans, Larisa | en_US |
dc.contributor.author | Pogozheva, Irina D. | en_US |
dc.contributor.author | Traynor, John R. | en_US |
dc.contributor.author | Mosberg, Henry I. | en_US |
dc.date.accessioned | 2014-02-11T17:56:56Z | |
dc.date.available | 2015-03-02T14:35:32Z | en_US |
dc.date.issued | 2014-01 | en_US |
dc.identifier.citation | Anand, Jessica P.; Porter‐barrus, Vanessa R. ; Waldschmidt, Helen V.; Yeomans, Larisa; Pogozheva, Irina D.; Traynor, John R.; Mosberg, Henry I. (2014). "Translation of structureâ activity relationships from cyclic mixed efficacy opioid peptides to linear analogues." Peptide Science 102(1): 107-114. | en_US |
dc.identifier.issn | 0006-3525 | en_US |
dc.identifier.issn | 1097-0282 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/102641 | |
dc.description.abstract | Most opioid analgesics used in the treatment of pain are mu opioid receptor (MOR) agonists. While effective, there are significant drawbacks to opioid use, including the development of tolerance and dependence. However, the coadministration of a MOR agonist with a delta opioid receptor (DOR) antagonist slows the development of MOR‐related side effects, while maintaining analgesia. We have previously reported a series of cyclic mixed efficacy MOR agonist/DOR antagonist ligands. Here we describe the transfer of key features from these cyclic analogs to linear sequences. Using the linear MOR/DOR agonist, Tyr‐DThr‐Gly‐Phe‐Leu‐Ser‐NH 2 ( DTLES ), as a lead scaffold, we replaced Phe 4 with bulkier and/or constrained aromatic residues shown to confer DOR antagonism in our cyclic ligands. These replacements failed to confer DOR antagonism in the DTLES analogs, presumably because the more flexible linear ligands can adopt binding poses that will fit in the narrow binding pocket of the active conformations of both MOR and DOR. Nonetheless, the pharmacological profile observed in this series, high affinity and efficacy for MOR and DOR with selectivity relative to KOR, has also been shown to reduce the development of unwanted side effects. We further modified our lead MOR/DOR agonist with a C‐terminal glucoserine to improve bioavailability. The resulting ligand displayed high efficacy and potency at both MOR and DOR and no efficacy at KOR. © 2013 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 102: 107–114, 2014. | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Mixed Efficacy | en_US |
dc.subject.other | Delta Opioid Receptor | en_US |
dc.subject.other | Homology Modeling | en_US |
dc.subject.other | Mu Opioid Receptor | en_US |
dc.title | Translation of structure‐activity relationships from cyclic mixed efficacy opioid peptides to linear analogues | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/102641/1/bip22437.pdf | |
dc.identifier.doi | 10.1002/bip.22437 | en_US |
dc.identifier.source | Peptide Science | en_US |
dc.identifier.citedreference | Polt, R.; Dhanasekaran, M.; Keyari, C. M. Med Res Rev 2005, 25, 557 – 585. | en_US |
dc.identifier.citedreference | El‐Andaloussi, S.; Holm, T.; Langel, U. Current Pharmaceutical Design 2005, 11, 3597 – 3611. | en_US |
dc.identifier.citedreference | Banks, W. A. Pept Sci 2008, 90, 589 – 594. | en_US |
dc.identifier.citedreference | Begley, D. J. Pharmacol Therapeutics 2004, 104, 29 – 45. | en_US |
dc.identifier.citedreference | Gray, A. C.; Coupar, I. M.; White, P. J. Life Sci 2006, 79, 674 – 685. | en_US |
dc.identifier.citedreference | Mansour, A.; Fox, C. A.; Akil, H.; Watson, S. J. Trends Neurosci 1995, 18, 22 – 29. | en_US |
dc.identifier.citedreference | Trescot, A. M.; Datta, S.; Lee, M.; Hansen, H. Pain Phys 2008, 11, S133 – S153. | en_US |
dc.identifier.citedreference | Keyari, C. M.; Knapp, B. I.; Bidlack, J. M.; Lowey, J.; Bilsky, E. J.; Polt, R. Adv Exp Med Biol 2009, 611, 495 – 496. | en_US |
dc.identifier.citedreference | Elmagbari, N. O.; Egleton, R. D.; Palian, M. M.; Lowery, J. J.; Schmid, W. R.; Davis, P.; Navratilova, E.; Dhanasekaran, M.; Keyari, C. M.; Yamamura, H. I.; Porreca, F.; Hruby, V. J.; Polt, R.; Bilsky, E. J. J Pharmacol Exp Therapeutics 2004, 311, 290 – 297. | en_US |
dc.identifier.citedreference | Egelton, R. D.; Mitchell, S. A.; Huber, J. D.; Palian, M. M.; Polt, R.; Davis, T. P. J Phamacol Exp Therapeutics 2001, 299, 967 – 972. | en_US |
dc.identifier.citedreference | Do Carmo, G. P.; Polt, R.; Bilsky, E. J.; Rice, K. C.; Negus, S. S. J Phamacol Exp Therapeutics 2008, 326, 939 – 948. | en_US |
dc.identifier.citedreference | Land, B. B.; Bruchas, M. R.; Lemos, J. C.; Xu, M.; Melief, E. J.; Chavkin, C. J Neurosci 2008, 28, 407 – 414. | en_US |
dc.identifier.citedreference | Pfeiffer, A.; Brantl, V.; Herz, A.; Emrich, H. M. Science 1986, 233, 774 – 776. | en_US |
dc.identifier.citedreference | Xuei, X.; Dick, D.; Flury‐Wetherill, L.; Tian, H. J.; Agrawal, A.; Beirut, L.; Goate, A.; Bucholx, K.; Schuckit, M.; Nurnberger, J.; Tischfield, J.; Kuperman, S.; Porjesz, B.; Begleiter, H.; Foroud, T.; Edenberg, H. J. Mol Psychiatry 2006, 11, 1016 – 1024. | en_US |
dc.identifier.citedreference | Lefever, M. R.; Szabo, L. Z.; Anglin, B.; Ferracane, M.; Hogan, J.; Cooney, L.; Polt, R. Carbohydr Res 2012, 351, 121 – 125. | en_US |
dc.identifier.citedreference | Mitchell, S. A.; Pratt, M. R.; Hruby, V. J.; Polt, R. J Organ Chem 2001, 66, 2327 – 2342. | en_US |
dc.identifier.citedreference | Lee, K. O.; Akil, H.; Woods, J. H.; Traynor, J. R. Eur J Pharmacol 1999, 323 – 330. | en_US |
dc.identifier.citedreference | Husbands, S. M.; Neilan, C. L.; Broadbear, J.; Grundt, P.; Breeden, S.; Aceto, M. D.; Woods, J. H.; Lewis, J. W.; Traynor, J. R. Eur J Pharmacol 2005, 117 – 135. | en_US |
dc.identifier.citedreference | Manglik, A.; Kruse, A. C.; Kobilka, T. S.; Thian, F. S.; Mathiesin, J. M.; Sunahara, R. K.; Pardo, L.; Weis, W. I.; Kobilka, B. K.; Grainer, S. Nature 2012, doi: 10.1038/nature10954. | en_US |
dc.identifier.citedreference | Granier, S.; Manglik, A.; Kruse, A., C.; Kobilka, T. S.; Thian, F. S.; Weis, W. I.; Kobilka, B. K. Nature 2012, 485, 400 – 404. | en_US |
dc.identifier.citedreference | Wu, H.; Wacker, D.; Mileni, M.; Katritch, V.; Han, G. W.; Vardy, E.; Lui, W.; Thompson, A. A.; Huang, X. P.; Carroll, F. I.; Mascarella, S. W.; Westkaemper, R. B.; Mosier, P. D.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Nature 2012, doi:10.1038/nature10939. | en_US |
dc.identifier.citedreference | Scheerer, P.; Park, J. H.; Hildebrand, P. W.; Kim, Y. J.; Krauss, N.; Choe, H. W.; Hofmann, K. P.; Ernst, O. P. Nature 2008, 455, 497 – 502. | en_US |
dc.identifier.citedreference | Rasmussen, S. G. F.; DeVree, B. T.; Zou, Y.; Kruse, A., C.; Chung, K. Y.; Kobilka, T. S.; Thian, F. S.; Chae, P. S.; Pardon, E.; Calinski, D.; Mathiesin, J. M.; Shah, S. T. A.; Lyons, J. A.; Caffery, M.; Gellman, S. H.; Steyaert, J.; Skiniotis, G.; Weis, W. I.; Sunahara, R. K.; Kobilka, B. K. Nature 2011, 477, 549 – 555. | en_US |
dc.identifier.citedreference | Lomize, A. L.; Flippen‐Anderson, J. L.; George, C.; Mosberg, H. I. J Am Chem Soc 1994, 116, 429 – 436. | en_US |
dc.identifier.citedreference | Morphy, R.; Kay, C.; Rankovic, Z. Res Focus Rev 2004, 9, 641 – 652. | en_US |
dc.identifier.citedreference | Morphy, R.; Rankovic, Z. Curr Pharm Des 2009, 15, 587 – 600. | en_US |
dc.identifier.citedreference | Dietis, N.; Guerrini, R.; Calo, G.; Salvadori, S.; Rowbotham, D. J.; Lambert, D. G. Br J Anaesthesia 2009, 103, 38 – 49. | en_US |
dc.identifier.citedreference | Heyman, J. S.; Jiang, Q.; Rothman, R. B.; Mosberg, H. I.; Porreca, F. Eur J Pharmacol 1989, 169, 43 – 52. | en_US |
dc.identifier.citedreference | Heyman, J. S.; Vaught, J. L.; Mosberg, H. I.; Haaseth, R. C.; Porreca, F. Eur J Pharmacol 1989, 165, 1 – 10. | en_US |
dc.identifier.citedreference | Horan, P.; Tallarida, R. J.; Haaseth, R. C.; Matsunaga, T. O.; Hruby, V. J.; Porreca, F. Life Sci 1992, 50, 1535 – 1541. | en_US |
dc.identifier.citedreference | Lowery, J. J.; Raymond, T. J.; Guivelis, D.; Bidlack, J. M.; Polt, R.; Bilsky, E. J. J Pharmacol Exp Therapeutics 2011, 336, 767 – 778. | en_US |
dc.identifier.citedreference | Abdelhamid, E. E.; Sultana, M.; Portoghese, P. S.; Takemori, A. E. J Pharmacol Exp Therapeutics 1991, 258, 299 – 303. | en_US |
dc.identifier.citedreference | Fundytus, M. E.; Schiller, P. W.; Shapiro, M.; Weltrowska, H.; Coderre, T. J. Eur J Pharmacol 1995, 286, 105 – 108. | en_US |
dc.identifier.citedreference | Hepburn, M. J.; Little, P. J.; Gringas, J.; Khun, C. M. J Pharmacol Exp Therapeutics 1997, 281, 1350 – 1356. | en_US |
dc.identifier.citedreference | Purington, L. C.; Pohozheva, I. D.; Traynor, J. R.; Mosberg, H. I. J Med Chem 2009, 52, 7724 – 7731. | en_US |
dc.identifier.citedreference | Schiller, P. W. Life Sci 2009, 86, 598 – 603. | en_US |
dc.identifier.citedreference | Purington, L. C.; Sobczyk‐Kojiro, K.; Pogozheva, I. D.; Traynor, J. R.; Mosberg, H. I. ACS Chem Biol 2011, 6, 1375 – 1381. | en_US |
dc.identifier.citedreference | Anathan, S.; Kezar, H. S.; Carter, R. L.; Saini, S. K.; Rice, K. C.; Wells, J. L.; Davis, P.; Xu, H.; Dersch, C. M.; Bilsky, E. J.; Porecca, F.; Rothman, R. B. J Med Chem 1999, 42, 3527 – 3538. | en_US |
dc.identifier.citedreference | Anathan, S.; Khare, N. K.; Saini, S. K.; Seitz, L. E.; Bartlett, J. L.; Davis, P.; Dersch, C. M.; Porreca, F.; Rothman, R. B.; Bilsky, E. J. J Med Chem 2004, 47, 1400 – 1412. | en_US |
dc.identifier.citedreference | Balboni, G.; Guerrini, R.; Salvadori, S.; Bianchi, C.; Rizzi, D.; Bryant, S. D.; Lazaruz, L. H. J Med Chem 2002, 45, 713 – 720. | en_US |
dc.identifier.citedreference | Balboni, G.; Salvadori, S.; Guerrini, R.; Negri, L.; Giannini, E.; Jinsmaa, Y.; Bryant, S. D.; Lazaruz, L. H. J Med Chem 2002, 45, 5556 – 5563. | en_US |
dc.identifier.citedreference | Cheng, K.; Kim, I. J.; Lee, M. J.; Adah, S. A.; Raymond, T. J.; Bilsky, E. J.; Aceto, M. D.; May, E. L.; Harris, L. S.; Coop, A.; Dersch, C. M.; Rothman, R. B.; Jacobson, A. E.; Rice, K. C. Organic Biomol Chem 2007, 5, 1177 – 1190. | en_US |
dc.identifier.citedreference | Heibel, A. C.; Lee, Y. S.; Bilsky, E. J.; Guivelis, D.; Deschamps, J. R.; Parrish, D.; Aceto, M. D.; May, E. L.; Harris, L. S.; Coop, A.; Dersch, C. M.; Partilla, J. S.; Rothman, R. B.; Cheng, K.; Jacobson, A. E.; Rice, K. C. J Med Chem 2005, 50, 3765 – 3776. | en_US |
dc.identifier.citedreference | Salvadori, S.; Guerrini, R.; Balboni, G.; Bianchi, C.; Bryant, S. D.; Cooper, P. S.; Lazaruz, L. H. J Med Chem 1999, 42, 5010 – 5019. | en_US |
dc.identifier.citedreference | Yamamoto, T.; Nair, P.; Vagner, J.; Largent‐Milnes, T.; Davis, P.; Ma, S. W.; Navratilova, E.; Moye, S.; Tumati, S.; Lai, J.; Yamamura, H. I.; Vanderah, T.; Porreca, F.; Hruby, V. J. J Med Chem 2008, 51, 1369 – 1376. | en_US |
dc.identifier.citedreference | Schiller, P. W.; Fundytus, M. E.; Merovitz, L.; Weltrowska, G.; Nguten, T. M.‐D.; Lemieux, C.; Chung, N. N.; Coderre, T. J. J Med Chem 1999, 42, 3520 – 3526. | en_US |
dc.identifier.citedreference | Schmidt, R.; Vogel, D.; Mrestani‐Klaus, C.; Brandt, W.; Neubert, K.; Chung, N. N.; Lemieux, C.; Schiller, P. W. J Med Chem 1994, 37, 1136 – 1144. | en_US |
dc.identifier.citedreference | Anand, J. P.; Purington, L. C.; Pogozheva, I. D.; Traynor, J. R.; Mosberg, H. I. Chem Biol Drug Design 2012, 80, 763 – 770. | en_US |
dc.identifier.citedreference | Lee, Y. S.; Kulkarani, V.; Cowell, S. M.; Ma, S. W.; Davis, P.; Hanlon, K. E.; Vanderah, T. W.; Lai, J.; Porreca, F.; Vardanyan, R.; Hruby, V. J. J Med Chem 2011, 54, 382 – 386. | en_US |
dc.identifier.citedreference | Horan, P. J.; Mattia, A.; Bilsky, E. J.; Weber, S.; Davis, T. P.; Yamamura, H. I.; Malatynska, E.; Appleyard, S. M.; Slaninova, J.; Misicka, A.; Lipkowski, A. W.; Hruby, V. J.; Porreca, F. J Phamacol Exp Therapeutics 1993, 265, 1446 – 1454. | en_US |
dc.identifier.citedreference | Fowler, C. B.; Pogozheva, I. D.; Lomize, A. L.; LeVine, H.; Mosberg, H. I. Biochemistry 2004, 43, 8700 – 8710. | en_US |
dc.identifier.citedreference | Fowler, C. B.; Pogozheva, I. D.; Lomize, A. L.; LeVine, H.; Mosberg, H. I. Biochemistry 2004, 43, 15796 – 15810. | en_US |
dc.identifier.citedreference | Pogozheva, I. D.; Lomize, A. L.; Mosberg, H. I. Biophysics 1997, 72, 1963 – 1985. | en_US |
dc.identifier.citedreference | Pogozheva, I. D.; Lomize, A. L.; Mosberg, H. I. Biophysics 1998, 75, 612 – 634. | en_US |
dc.identifier.citedreference | Pogozheva, I. D.; Przydzial, M. J.; Mosberg, H. I. AAPS J 2005, 7, 43 – 57. | en_US |
dc.identifier.citedreference | Gacel, G.; Dauge, V.; Breuze, P.; Delay‐Goyet, P.; Roques, B. P. J Med Chem 1988, 31, 1891 – 1897. | en_US |
dc.identifier.citedreference | Li, Y.; Lefever, M. R.; Muthu, D.; Bidlack, J. M.; Bilsky, E. J.; Polt, R. Future Med Chem 2012, 4, 205 – 226. | en_US |
dc.identifier.citedreference | Sasaki, Y.; Suto, T.; Ambo, A.; Ouchi, H.; Yamamoto, Y. Cell Pharmacol Bull 1999, 47, 1506 – 1509. | en_US |
dc.identifier.citedreference | Bailey, C. P.; Connor, M. Current Opin Pharmacol 2005, 5, 60 – 68. | en_US |
dc.identifier.citedreference | Carroll, F. I.; Carlezon, W. A. J Med Chem 2013, 56, 2718 – 2195. | en_US |
dc.identifier.citedreference | Rozenfeld, R.; Abul‐Husn, N. S.; Gomez, I.; Devi, L. A. Sci World J 2007, 7, 4 – 73. | en_US |
dc.identifier.citedreference | Egleton, R. D.; Davis, T. P. NeuroRx 2005, 44 – 53. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.